drugset / Trial / NCT03611153
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 1/2
Completed
30 enrolled
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Timeline
- Start
- 2018-07-01
- Primary completion
- 2022-02-11
- Completion
- 2022-02-24
Outcome
Missed primary endpoint
registry MEAN AZD4831 Oral Myeloperoxidase Inhibitor: -1 (Standard Deviation 3) mmHg NCT03611153 ↗
registry MEAN Placebo: -4 (Standard Deviation 5) mmHg NCT03611153 ↗
registry analysis (superiority test); AZD4831 Oral Myeloperoxidase Inhibitor vs Placebo; p = 0.040; ANCOVA NCT03611153 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitiperstat | Small molecule | 30 mg | Oral |